What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Benzinga09-10

Monday, Immunovant, Inc. (NASDAQ:IMVT) reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466113429?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l7qwqxNzpBSZJRbb83.Byg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2666d1db27f3612d82e18134e270e74c","is_english":true,"pubTime":"2024-09-10 00:54","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2466113429","market":"us","top_or_hot":-1,"title":"What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?","media":"Benzinga","content":"<div>\n<p>Monday, Immunovant, Inc. (NASDAQ:IMVT) reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make ...</p>\n\n<a href=\"https://finance.yahoo.com/news/whats-going-vivek-ramaswamy-founded-165413401.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-10 00:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/whats-going-vivek-ramaswamy-founded-165413401.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Monday, Immunovant, Inc. (NASDAQ:IMVT) reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make ...</p>\n\n<a href=\"https://finance.yahoo.com/news/whats-going-vivek-ramaswamy-founded-165413401.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMVT","symbol_name":"Immunovant, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/whats-going-vivek-ramaswamy-founded-165413401.html","article_id":"2466113429","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l7qwqxNzpBSZJRbb83.Byg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/2666d1db27f3612d82e18134e270e74c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466113429","pubTimestamp":1725900853,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Monday, Immunovant,Inc.  reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.Immunovant is a member of theRoivant Sciences Ltd. family of companies.Also Read: Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study.As previously disclosed, the batoclimab phase 2a trial in uncontrolled Graves’ Disease enrolled patients who were hyperthyroid despite antithyroid drugs  therapy.Participants in the trial received 12 weeks of high-dose batoclimab, 680 mg weekly by subcutaneous injection  followed by 12 weeks of lower-dose batoclimab, 340 mg weekly SC.At the end of the first 12 weeks, participants experienced a mean IgG reduction of 77%, leading to a 76% Response rate.In addition, by the end of 12 weeks of higher dose batoclimab, 56% achieved an ATD-Free Response.Despite benefiting from a lower starting IgG level after 12 weeks of 680mg th","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMVT":"Immunovant, Inc.","BK4585":"ETF&股票定投概念","BK4588":"碎股","ROIV":"Roivant Sciences Ltd.","BK4139":"生物科技","BK4007":"制药"},"translate_title":"Vivek Ramaswamy创立的Roivant Sciences股票周一走势如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ROIV":1,"IMVT":0.9},"content_text":"Monday, Immunovant, Inc. (NASDAQ:IMVT) reported results from the Phase 2a trial of batoclimab in Graves’ Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone.\nImmunovant is a member of the Roivant Sciences Ltd. (NASDAQ:ROIV) family of companies.\nAlso Read: Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study.\nAs previously disclosed, the batoclimab phase 2a trial in uncontrolled Graves’ Disease enrolled patients who were hyperthyroid despite antithyroid drugs (ATD) therapy.\nParticipants in the trial received 12 weeks of high-dose batoclimab, 680 mg weekly by subcutaneous injection (SC) followed by 12 weeks of lower-dose batoclimab, 340 mg weekly SC.\nAt the end of the first 12 weeks, participants experienced a mean IgG reduction of 77%, leading to a 76% Response rate.\nIn addition, by the end of 12 weeks of higher dose batoclimab, 56% achieved an ATD-Free Response.\nDespite benefiting from a lower starting IgG level after 12 weeks of 680mg therapy, during Weeks 13 to 24, the lower 340mg dose of batoclimab resulted in a mean IgG reduction of 65% (vs. 77% on 680mg dose) with a corresponding lower responder rate of 68%.\nIn the second 12 weeks, a 36% lower ATD-Free Response rate was also observed.\nFinally, patients who achieved at least a 70% IgG reduction at the end of the trial had nearly a threefold higher ATD-Free Response rate than those who did not (60% vs. 23%).\n“We find the correlation between clinical response and IgG lowering impressive and believe this creates not only a potential first-in-class but also a potential best-in-class opportunity for IMVT-1402. We are very pleased to have aligned with the FDA on a pivotal trial design that we expect to initiate by the end of the year,” said Pete Salzmann, CEO of Immunovant.\nImmunovant also announced alignment with the FDA and Investigational New Drug Application clearance, with the initiation of a pivotal trial of IMVT-1402 in Graves’ Disease expected by December 31, 2024.\nPrice Action: ROIV stock is up 4.67% at $12.88, and IMVT stock is down 0.32% at $33.92 at last check Monday.\nRead Next:\n\nFDA Gives Green Signal To Rezolute’s Genetic Disorder Treatment.\n\n\"ACTIVE INVESTORS' SECRET WEAPON\" Supercharge Your Stock Market Game with the #1 \"news & everything else\" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!\nGet the latest stock analysis from Benzinga?\n\nThis article What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466113429"}